[go: up one dir, main page]

AU1572701A - Treating wasting syndromes with aryloxy propanolamines - Google Patents

Treating wasting syndromes with aryloxy propanolamines

Info

Publication number
AU1572701A
AU1572701A AU15727/01A AU1572701A AU1572701A AU 1572701 A AU1572701 A AU 1572701A AU 15727/01 A AU15727/01 A AU 15727/01A AU 1572701 A AU1572701 A AU 1572701A AU 1572701 A AU1572701 A AU 1572701A
Authority
AU
Australia
Prior art keywords
wasting syndromes
treating wasting
propanolamines
aryloxy
aryloxy propanolamines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU15727/01A
Inventor
Deana Lori Hancock
Randall Bruce Hopkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU1572701A publication Critical patent/AU1572701A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU15727/01A 1999-11-15 2000-11-13 Treating wasting syndromes with aryloxy propanolamines Abandoned AU1572701A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16546499P 1999-11-15 1999-11-15
US60165464 1999-11-15
PCT/US2000/028889 WO2001035947A2 (en) 1999-11-15 2000-11-13 Treating wasting syndromes with aryloxy propanolamines

Publications (1)

Publication Number Publication Date
AU1572701A true AU1572701A (en) 2001-05-30

Family

ID=22599002

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15727/01A Abandoned AU1572701A (en) 1999-11-15 2000-11-13 Treating wasting syndromes with aryloxy propanolamines

Country Status (2)

Country Link
AU (1) AU1572701A (en)
WO (1) WO2001035947A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1580101A (en) 1999-11-15 2001-05-30 Eli Lilly And Company Indazolyloxy propanolamines for improving livestock production
CA2426730A1 (en) * 2000-10-25 2002-05-16 Smithkline Beecham Corporation Calcilytic compounds
CA2421594A1 (en) 2000-11-10 2002-05-16 John Arnold Werner 3-substituted oxindole beta 3 agonists
DE60215028T2 (en) 2001-08-14 2007-03-15 Eli Lilly And Co., Indianapolis INDOL DERIVATIVES AS BETA-3-ADRENERGE AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES
WO2003016276A2 (en) 2001-08-14 2003-02-27 Eli Lilly And Company 3-substituted oxindole beta-3 agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
AU2002347982A1 (en) 2001-11-20 2003-06-10 Eli Lilly And Company 3-SUBSTITUTED OXINDOLE Beta3 AGONISTS
ES2299618T3 (en) 2001-11-20 2008-06-01 Eli Lilly And Company BETA-3-ADRENERGIC AGONISTS.
JP2005520805A (en) * 2002-01-11 2005-07-14 イーライ・リリー・アンド・カンパニー 2-Oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
US7317023B2 (en) 2004-07-21 2008-01-08 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
EP2903452A1 (en) * 2012-10-02 2015-08-12 Eli Lilly and Company Methods for improving chicken production
GB202213163D0 (en) * 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2266497B1 (en) * 1974-04-03 1977-11-04 Roussel Uclaf
CA1262729A (en) * 1983-10-19 1989-11-07 Leo Alig Phenoxypropanolamines
GB9224740D0 (en) * 1992-11-26 1993-01-13 Ici Plc Therapeutic agents
US5597843A (en) * 1995-06-07 1997-01-28 Houghten Pharmaceuticals Use of a substituted 1,3-benzodioxole to reduce a wasting condition
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
PL325865A1 (en) * 1995-09-21 1998-08-17 Lilly Co Eli Selective antagonists of beta3-adrenergic receptor
ATE215369T1 (en) * 1996-09-05 2002-04-15 Lilly Co Eli CARBAZOLE ANALOGUES AS SELECTIVE BETA3-ADRENERGIC AGONISTS
FR2755439B1 (en) * 1996-11-05 1998-12-24 Virbac Sa ARYLOXYPROPANOLAMINE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS
CO5011072A1 (en) * 1997-12-05 2001-02-28 Lilly Co Eli ETANOLAMINAS PIRAZINIL SUBSTITUTED AS AGFONISTS OF THE RECEPTORS
AUPP796798A0 (en) * 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound

Also Published As

Publication number Publication date
WO2001035947A3 (en) 2001-11-22
WO2001035947A2 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
GB2352834B (en) Fibre-optics
AU3701800A (en) Indexed pallet
GB9919477D0 (en) Substrate conveyors
AU4132000A (en) Diphenylurea derivatives
AU1572701A (en) Treating wasting syndromes with aryloxy propanolamines
AU4439700A (en) Insulator
AU5165700A (en) Terminal design
AU4963700A (en) Pallet
AU5671200A (en) Photovoltaic sun-blind element
AU4026400A (en) Clamp assembly
EP1175130A4 (en) Electroluminescent element
IL149168A0 (en) Small arms
AU3436100A (en) Candle
GB2351756B (en) Trellis assemblies
AU3610300A (en) Single-stage-to-orbit rocket
AU7550100A (en) Central heating
AU4351900A (en) Inducible vaccines
AU7677700A (en) Solar heater arrangement
TW461664U (en) PTC heating-structure with electric-less fin-plates
GB9901307D0 (en) ABC clamp
HK1050139A (en) Polyanhydrides with biologically active degradation products
GR990200116U (en) Garlands with balloons
AUPQ271299A0 (en) Insulator shrouds
AUPQ016899A0 (en) Mow-less collars
GB9925015D0 (en) Immunosuppression

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase